Literature DB >> 17441537

Prevalence and associated factors of hepatitis C infection (HCV) in a multi-site Canadian population of illicit opioid and other drug users (OPICAN).

Michelle Firestone Cruz1, Benedikt Fischer, Jayadeep Patra, Kate Kalousek, Brenda Newton-Taylor, Jürgen Rehm, Mark Tyndall.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is highly prevalent in illicit drug user populations, with three in four new HCV infections related to this risk behaviour and a growing HCV disease burden in Canada. Using data from a multi-site cohort study of illicit opioid users in five Canadian cities (OPICAN), this paper explores the prevalence and predictors of HCV status in this high-risk population.
METHODS: HCV status of cohort participants was assessed by salivary antibody test. Univariate relationships of HCV status with select variables were examined on the basis of cohort baseline data, and subsequently multivariate models using logistic regression to determine independent predictors of HCV status were generated.
RESULTS: 54.6% of the analysis sample (n=482) was HCV positive. Significant differences in terms of HCV prevalence existed across the sites. Significant variables in the final stepwise logistic regression model included age, site (Toronto), unprotected sex, injecting drug use, drug treatment and incarceration in past year, in addition to opioid use in combination with non-opioids. DISCUSSION: Besides drug injecting, various other socio-behavioural factors were associated with HCV status in our cohort. On this basis, interventions focusing solely on injection risks are overly limited in scope to prevent HCV transmission in the high-risk population of illicit drug users and need to be broadened. Prevention efforts should also target young injectors as a priority.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17441537

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  8 in total

1.  Prevalence of HCV risk behaviors among prison inmates: tattooing and injection drug use.

Authors:  Marisol Peña-Orellana; Adriana Hernández-Viver; Glorimar Caraballo-Correa; Carmen E Albizu-García
Journal:  J Health Care Poor Underserved       Date:  2011-08

Review 2.  Risk of window period hepatitis-C infection in high infectious risk donors: systematic review and meta-analysis.

Authors:  L M Kucirka; H Sarathy; P Govindan; J H Wolf; T A Ellison; L J Hart; R A Montgomery; R L Ros; D L Segev
Journal:  Am J Transplant       Date:  2011-03-14       Impact factor: 8.086

3.  Correlates of incarceration among young methamphetamine users in Chiang Mai, Thailand.

Authors:  Nicholas Thomson; Catherine G Sutcliffe; Bangorn Sirirojn; Rassamee Keawvichit; Kanlaya Wongworapat; Kamolrawee Sintupat; Apinun Aramrattana; David D Celentano
Journal:  Am J Public Health       Date:  2008-10-15       Impact factor: 9.308

4.  Guidance on the use of increased infectious risk donors for organ transplantation.

Authors: 
Journal:  Transplantation       Date:  2014-08-27       Impact factor: 4.939

Review 5.  Associated Factors of Maintenance in Patients under Treatment with Methadone: A Comprehensive Systematic Review and Meta-Analysis.

Authors:  Farzaneh Farmani; Hadi Farhadi; Younes Mohammadi
Journal:  Addict Health       Date:  2018-01

6.  Add-On Selective Estrogen Receptor Modulators for Methadone Maintenance Treatment.

Authors:  Chieh-Liang Huang; Yao-Chang Chiang; Wei-Chun Chang; Yu-Ting Su; Juan-Cheng Yang; Wei-Chung Cheng; Hsien-Yuan Lane; Ing-Kang Ho; Wen-Lung Ma
Journal:  Front Endocrinol (Lausanne)       Date:  2021-08-05       Impact factor: 5.555

7.  Sex differences in outcomes of methadone maintenance treatment for opioid addiction: a systematic review protocol.

Authors:  Monica Bawor; Brittany B Dennis; Rebecca Anglin; Meir Steiner; Lehana Thabane; Zainab Samaan
Journal:  Syst Rev       Date:  2014-05-16

8.  Hepatitis C avoidance in injection drug users: a typology of possible protective practices.

Authors:  Catherine McGowan; Magdalena Harris; Tim Rhodes
Journal:  PLoS One       Date:  2013-10-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.